

Doe, Jane (Id: 0000000)

Date Of Birth: 01/01/2001

Gender: Female

Ordering Provider

Sample Information

Accession: 6901203MPID

Specimen: Oral Rinse

Collected: 09/08/2009 10:48

Received: 09/09/2009 10:48

Reported: 09/14/2009 13:48

Printed: 09/16/2009 13:48

Result:

POSITIVE

Results:

IL-1A (+4845) Genotype **T/T**IL-1B (+3954) Genotype **C/T**

Interpretation:

The results of the PST test indicate that your patient is **POSITIVE** and has an increased risk for more severe periodontal disease due to the genetic variations examined in this test. PST-positive patients may require more aggressive treatment.

Comments:

- **Significance:** This individual has the "PST-positive" genotype and is therefore at a 3-7 fold increased risk for severe periodontal disease. The PST composite genotype is based on the combination of the results for the IL-1A and IL-1B genes. Any combination that includes the presence of a "T" at both IL-1A (+4845) and IL-1B (+3954) is defined as PST-positive and predisposes an individual to more severe periodontal disease which may require more aggressive treatment.
- **Risk:** Prevalence of the PST-positive genotype ranges from 30 to 40% in Caucasian populations. This frequency may be different in other ethnic groups. It is important to note that whenever the PST-positive genotype is present, it is associated with an increased susceptibility to periodontal disease and overproduction of IL-1, a cytokine that amplifies inflammation.
- **Consider:** The PST test assesses one of several risk factors that should be included in an overall evaluation of periodontal disease. Specific bacteria are associated with the initiation of the disease, and additional risk factors including genetic susceptibility, smoking, diabetes, and oral hygiene have an amplifying effect on periodontal disease progression.

Methodology: Genomic DNA is extracted and tested for two Interleukin-1 polymorphisms. These polymorphisms are tested via polymerase chain reaction (PCR), followed by melt curve analysis.

Disclaimer: 1. OralDNA is not liable for any outcomes arising from clinician's treatment protocols and decisions. Dentists should consult with a periodontist or patient's physician when infections are advanced or as indicated by patient's medical condition. 2. OralDNA is not responsible for inaccurate test results due to poor sample collection. 3. This test was developed and its performance characteristics determined by OralDNA Labs. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

OralDNA Labs, Inc., 214 Overlook Circle, Suite 120, Brentwood, TN 37027 6155779055; Fax: 6156272826 www.oraldna.com

Medical Director: Ronald McGlennen, MD

Chief Dental Officer: Thomas W. Nabors, DDS